Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.
about
Tyrosine Kinase Inhibitors for the ElderlyErlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management.
P2860
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Erlotinib for elderly patients ...... ive (POSITIVE) Research Group.
@en
Erlotinib for elderly patients ...... e Ibaraki Thoracic Integrative
@nl
type
label
Erlotinib for elderly patients ...... ive (POSITIVE) Research Group.
@en
Erlotinib for elderly patients ...... e Ibaraki Thoracic Integrative
@nl
prefLabel
Erlotinib for elderly patients ...... ive (POSITIVE) Research Group.
@en
Erlotinib for elderly patients ...... e Ibaraki Thoracic Integrative
@nl
P2093
P2860
P356
P1476
Erlotinib for elderly patients ...... ive (POSITIVE) Research Group.
@en
P2093
Akihiro Nomura
Hideo Ichimura
Hiroaki Satoh
Hiroichi Ishikawa
Hiroyuki Nakamura
Katsunori Kagohashi
Keiko Uchiumi
Kenji Hayashihara
Kinya Furukawa
Koichi Kamiyama
P2860
P304
P356
10.3892/MCO.2013.154
P577
2013-07-23T00:00:00Z